A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTRT) in esophageal adenocarcinoma (EC).
Weiwei Shan
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Natalie Lassen
Research Funding - Castle Biosciences
Clare Johnson
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Yaeli Biermann-Harrar
No relevant relationships to disclose
Kristen M. Oelschlager
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Robert W. Cook
Stock Ownership - Castle Biosciences
Research Funding - Castle Biosciences
Daniel Rosen
No relevant relationships to disclose
Sunil S. Badve
No relevant relationships to disclose
Kenneth Kessler
No relevant relationships to disclose
Romil Saxena
No relevant relationships to disclose